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Alzheimer’s in a dish – induced pluripotent
stem cell-based disease modeling
Sherida de Leeuw1,2 and Christian Tackenberg1,2*
Abstract
Background: Since the discovery of the induced pluripotent stem cell (iPSC) technique more than a decade ago,
extensive progress has been made to develop clinically relevant cell culture systems. Alzheimer’s disease (AD) is the
most common neurodegenerative disease, accounting for approximately two thirds of all cases of dementia. The
massively increasing number of affected individuals explains the major interest of research in this disease as well as
the strong need for better understanding of disease mechanisms.
Main body: IPSC-derived neural cells have been widely used to recapitulating key aspects of AD. In this Review we
highlight the progress made in studying AD pathophysiology and address the currently available techniques, such
as specific differentiation techniques for AD-relevant cell types as well as 2D and 3D cultures. Finally, we critically
discuss the key challenges and future directions of this field and how some of the major limitations of the iPSC
technique may be overcome.
Conclusion: Stem cell-based disease models have the potential to induce a paradigm shift in biomedical research.
In particular, the combination of the iPSC technology with recent advances in gene editing or 3D cell cultures
represents a breakthrough for in vitro disease modeling and provides a platform for a better understanding of
disease mechanisms in human cells and the discovery of novel therapeutics.
Keywords: Alzheimer’s disease, Induced pluripotent stem cells, iPSC-derived neurons, iPSC-derived astrocytes, iPSC-
derived microglia, Disease modeling
Background
AD is the most common age-related neurodegenerative
disease affecting memory and executive functions up to
behavioral and neuropsychiatric changes in late stages.
An estimated 40 million people, mostly older than 60
years, have dementia worldwide, and this number is ex-
pected to double every 20 years, until at least 2050 [1].
The World Health Organization predicts that by 2040,
neurodegenerative disease will overtake cancer to be-
come the second leading cause of death after cardiovas-
cular diseases [2]. Thus, understanding cellular and
molecular pathomechanisms of these disorders is of
major importance. Current approved AD therapies are
only symptomatic, and no treatment exists to fully stop
progression or prevent disease onset.
For decades, primary rodent cell cultures represented
the gold standard of mammalian in vitro systems. Des-
pite a significant gain of knowledge on basic neural cell
biology and disease pathophysiology obtained from
these cells, translation to clinical research remains chal-
lenging. Cellular functions, morphology or expression
of several disease-relevant proteins such as ApoE
strongly differs between rodent and human cells (see
following chapters). The establishment of the iPSC
culture technique represents one of the most important
innovations in biomedical research in this century. By
reprogramming somatic human cells into an embryonic
stem cell-like state, pluripotent cells are generated
which can be further differentiated into virtually any
somatic cell. The combination with gene editing tech-
niques such as CRISPR/Cas9 further increases the value
of this technique. The newest achievements are 3D
models or self-organizing organoids which resemble
patient-in-a-dish models of organs and can even display
key features of organ-specific cytoarchitecture [3, 4].
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Here we review the current research on iPSC-based
modeling of AD, highlight current advances and discuss
future challenges of the iPSC technology.
Main text
Alzheimer’s disease pathophysiology
Aggregates of Aβ and hyperphosphorylated tau, i.e. extra-
cellular amyloid plaques and intracellular neurofibrillary
tangles are the major hallmarks of AD. The 40-residue
peptide Aβ40 represents the most abundant Aβ isoform in
the brain while the 42-residue Aβ42 is the more neuro-
toxic peptide. Aβ is a processing product of the amyloid
precursor protein, APP, which is metabolized by two dis-
tinct pathways, the amyloidogenic and non-amyloidogenic
pathway. In the latter, which takes place in the endosomal
compartment [5], processing of APP by β-secretase
(BACE1) generates sAPPβ, the soluble N-terminal ectodo-
main, and the membrane-bound C99 fragment (Fig. 1).
Subsequent cleavage of C99 by γ-secretase causes the pro-
duction of Aβ which is released from the cell and was ori-
ginally thought the be the main trigger of AD (also
postulated as the “amyloid-hypothesis”) [6], especially in
an oligomeric state. Further, APP intracellular domain
(AICD) is generated, which can translocate to the nucleus
to regulate transcription of approximately 30 genes [7]. In
the alternative, non-amyloidogenic pathway α-secretase
cleavage at the cell surface generates the C83 fragment
and causes the release of sAPPα which has been proposed
to be neuroprotective [8, 9]. The α-secretase cleaves APP
within the Aβ domain, hence precluding the production
of Aβ. However, subsequent processing of C83 by γ-
secretase generates a fragment called p3 (Aβ17-X). While
p3 is not amyloidogenic, it is found in non-congophilic
plaques in patients with Down Syndrome and AD, and its
relevance for AD pathophysiology is not yet understood
[10]. Although most research is conducted on the role of
extracellular Aβ, evidence exists that also intracellular de-
posited Aβ contributes to AD pathology, and that accu-
mulation of intraneuronal Aβ is an early event in the
progression of AD, preceding extracellular amyloid pla-
ques [11].
The microtubule-associated protein tau has six isoforms
which vary in length due to alternative splicing of exons 2,
3 and 10. Three isoforms contain 3 microtubule-binding
repeats (3RTau) the other three isoforms contain 4 repeats
(4RTau). In embryonic cells only one of the 3RTau
isoforms is expressed, whereas mature neurons show
Fig. 1 Schematic representation of APP processing
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presence of all six isoforms. Tau belongs to the major
phosphoproteins in the brain. In the AD brain, tau is ab-
normally phosphorylated. In addition, tau is subjected to
other posttranslational modifications which may further
contribute to its pathologic role in AD, such as acetylation
or N- and C-terminal truncation (reviewed in [12]). These
modifications lead to altered tau folding thereby increas-
ing its aggregation propensity. Aberrantly modified tau
mediates toxicity downstream of Aβ [13–15] and knock-
out of endogenous tau abolished axonal transport deficits
in APP transgenic mice [16] confirming its essential role
in AD.
Genetically, AD is divided into two forms, familial (fAD)
and sporadic AD (sAD). Familial cases have a predomin-
antly early-onset (< 60 years, also called early-onset AD
(EOAD)) while sAD cases with no or less familial evidence
have later age of onset (> 60 years, late-onset AD (LOAD))
[17]. FAD mutations either 1) increase the total produc-
tion of Aβ, 2) shift the production to more toxic and
aggregation-prone Aβ42 or 3) increase the aggregation
propensity of the peptide, depending whether the muta-
tion is localized 1) around the β-secretase cleavage, 2) at
the γ–secretase cleavage site or 3) within the Aβ sequence
[18]. This explains the increased Aβ deposition in the
brains of fAD patients. However, fAD accounts for less
than 1% of all AD cases [19]. The strongest nongenetic
risk factors for sAD are age, medical factors such as dia-
betes mellitus, high blood pressure or hypercholesterol-
emia as well as socioeconomic factors such as low
education or lack of social contacts [20]. Although sAD is
not associated with mutations that ultimately cause dis-
ease onset, genetic risk genes play a role in at least 80% of
all AD cases [21]. The major genetic risk factor is the
presence of the apolipoprotein 4 (APOE4) allele. ApoE
is a glycoprotein expressed mainly in the liver and in the
brain. It is involved in transport of cholesterol across dif-
ferent tissues and cells and has been implicated in neur-
onal growth and repair, immune response, and activation
of lipolytic enzymes [22]. ApoE has three different iso-
forms, ApoE2, ApoE3 and ApoE4, which differ only in
two amino acid residues. While APOE3/3 is the most
common genotype and does not affect the AD risk, the
presence of one or two copies of APOE4 increases the risk
by tree or twelve fold, respectively [23]. In vitro, ApoE4
has been shown to enhance aggregation of Aβ compared
to ApoE3 [24]. Analyses of ApoE in mouse models show
that ApoE4 is associated with increased levels of Aβ, as
well as amyloid plaque deposition [25]. Furthermore, the
different ApoE isoforms may differentially affect energy
metabolism, neuroinflammation and synaptic function
[26]. More risk genes have been identified with different
population frequencies and odds ratios including TREM2,
BIN1, CLU, SORL1, ABCA7, CD33 and others (reviewed
in [27, 28]).
Many of the AD risk genes show highest expression in
glia, i.e. astrocytes (e.g. APOE, CLU, SORL1) or microglia
(e.g. TREM2, CD33) [28] highlighting the importance of
glia, especially microglia and astrocytes, for AD patho-
physiology. In our opinion, in the last decade research
focused too much on neurons, disregarding the role of
glia. However, this recently changed and consequently,
the number of studies in iPSC-derived glia increases and
new differentiation protocols to obtain human astrocytes
and microglia are being developed (see chapter Differen-
tiation into disease-relevant cell types). Human glia
structurally and functionally differs from murine glia
[29–32]. Hence, the use of human iPSC-derived glia is of
high importance to i) verify already existing data from
animal studies and ii) acquire new insights into the
mechanisms by which human glia contribute to the
pathogenesis of sAD.
iPSCs and disease modeling
Stem cells are defined by the ability to undergo self-
renewal, while maintaining an undifferentiated state, and
to differentiate into specialized cell types (potency). IPS
cells are undifferentiated cells, which have been repro-
grammed to an embryonic stem cell (ESC)-like state by
expression of defined factors. Thus, many protocols
established for ESC culture are applicable for iPSCs as
well. However, in contrast to embryonic stem cells,
iPSCs can be utilized without concerns of ethical issues
or allogeneic immune response when used in regenera-
tive medicine. In 2006 the group of Shinya Yamanaka
was the first to generate iPSCs from mouse fibroblasts
[33], followed by human fibroblasts in 2007 [34]. Repro-
gramming was induced by retroviral expression of initial
reprogramming factors Oct4 (also called Oct3/4 or
Pou5f1), Sox2, Klf4, and c-Myc (together termed
OSKM). Over the years, additional factors which in-
creased reprogramming efficiency were discovered, and
the combinations of different factors have been refined.
Okita and colleagues compared several factor combina-
tions and found that forced expression of RNA-binding
protein Lin28, p53shRNA and l-Myc (instead of c-Myc),
together with Oct4, Sox2 and Klf4 significantly increased
the yield of iPSC colonies after reprogramming human
fibroblasts [35]. Creation of a hypoxic environment dur-
ing reprogramming was found to lead higher numbers
of colonies [36]. Further, addition of ascorbic acid, inhib-
ition of GSK3-β [37] or activation of Wnt signaling [38]
improved iPSC yield. Moreover, inhibition of histone
deacetylases by treatment with sodium butyrate or val-
proic acid, enhanced the reprogramming process [39,
40]. IPSCs have been generated from many different cell
types, including fibroblasts, keratinocytes, cord blood
endothelial cells, melanocytes, hepatocytes, T-cells or
peripheral blood mononuclear cells, using different
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combinations of reprogramming factors [41]. Typical
iPSC colonies are characterized by a defined edge and
expression of pluripotency markers such as Nanog, Oct4
or Tra-1-60 (Fig. 2).
Since the development of the iPSC technology, a
major concern included the use of inserting retro vi-
ruses into the genome, which may cause inadvertent
effects such as tumorigenesis. To circumvent these
limitations, non-integrative techniques were
established, including episomal vectors [35, 42],
Sendai-virus [43], mRNA transfection [44] or
piggyback-mediated OSKM transposition [45].
A further limitation, especially for modeling age-
related diseases, is the lack of maturity and aging-
Fig. 2 Reprogramming of human fibroblasts (hFib) to iPSCs. a Human skin biopsy-derived fibroblasts in culture. [1] hFib growing out of the
biopsy (black). [2] Phase contrast image of isolated hFib. [3] hFib stained with Alexa Fluor 488 Phalloidin. b IPSC colonies after reprogramming. [1]
Light microscopic image of a single iPSC colony. [2–6] Immunostained iPSC colonies showing expression of typical pluripotency marker proteins.
[2] DAPI, [3] Oct4, [4] Tra-1-60, [5] Nanog, [6] merged images
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signatures of iPSC-derived neural cells. During repro-
gramming of somatic cells into iPSCs the cellular
aging profile is widely erased [46]. Accordingly, neu-
rons differentiated from iPSCs display a fetal, imma-
ture phenotype and lack the aging signatures of their
source cells [47]. Cellular senescence is characterized
by reduction in DNA methylation, heterochromatin,
telomere length or nuclear lamina integrity and in-
crease in DNA damage, reactive oxygen species (ROS)
formation, or expression of senescence-associated β-
galactosidase. Interestingly, fibroblasts from patients
suffering from Hutchinson Gildford progeria syn-
drome, a disease of premature ageing, show these in-
creased senescence signs [48]. HGPS is caused by
mutations in the gene for nuclear envelope protein
lamin A, resulting in the production of shorter tran-
script, called progerin. Accordingly, expression of pro-
gerin in iPSC-derived neurons induced multiple
aging-related characteristics and may facilitate the
analysis of late-onset disease features in iPS-derived
cells [47]. Another study found the nuclear transport
receptor RAN binding protein 17 (RanBP17) to be a
master regulator of aging in fibroblasts and iN cells
and showed that knock-down of RanBP17 induced
cellular aging by disruption of nucleocytoplasmic
compartmentalization [49]. A way to circumvent cell
rejuvenation during iPSC reprogramming is the direct
conversion (transdifferentiation) of fibroblasts into
neurons (Fig. 3). This can be achieved by overexpres-
sion of defined transcription factors [49, 50] or
microRNA/transcription factor combinations [51, 52].
These directly converted neurons, called induced
neuronal cells (iN cells), retain their aging profile and
displayed age-related disease phenotypes when taken
from Huntington’s or Parkinson’s patients [47, 53].
Nevertheless, the iPSC approach has several advantages
over transdifferentiated cells as it permits obtaining large
numbers of cells which can be kept in culture theoretically
indefinitely and allows gene-editing at this stage. Gene
editing technologies further increase the power of iPSCs
for both, disease-modeling and regenerative therapies.
IPSC-based disease modeling can principally be achieved
by two different approaches, a patient-specific and an iso-
genic approach (Fig. 4). Several studies generated iPSCs
from sAD or fAD patients and determined AD-related
phenotypes compared to cells from healthy control sub-
jects (see chapter AD pathophysiology in iPSC-derived
cells for more details). While this approach is a first and
important step to gain insights into AD pathomechan-
isms, the interpretation of the obtained data must be
taken with care. Due to high genetic variability between
individuals, the observed finding cannot be linked to the
disease progression of the respective patient with full cer-
tainty. As gene-editing technologies become more and
more easy applicable and cell banks arise providing large
stocks of gene-edited iPS cell lines, we recommend using
the isogenic approach wherever possible. In this approach
genome-editing such as CRISPR/Cas9 is used to either
correct a mutation in cells from a fAD patient or to intro-
duce a mutation in cells from HCSs. These cells are then
compared to their parental (isogenic) line thereby elimin-
ating bias caused by interpatient genetic variation. This
approach can even be used to model sAD, for example by
introducing/mutating AD risk genes such as APOE.
Fig. 3 Common ways to generate human neural cells for modeling Alzheimer’s disease. Somatic cells may either be directly converted into
induced neuronal (iN) cells (transdifferentiation) or reprogramed into iPSCs. Neural induction – mainly by dual-smad inhibition – yields NPCs,
which can further be differentiated into neuron and astrocytes, either pure or of mixed-types. Alternatively, iPSCs can be directly converted to
neurons (also called iN cell in this case) by forced expression of transcription factors such as neurogenin2, omitting the NPC step. Microglial cells
can be obtained by iPSC differentiation into erythromyeloid progenitors (EMPs) which are further differentiated to microglia. However, few
alternative protocols achieve microglial differentiation via NPCs
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Differentiation into disease-relevant cell types
Neuronal cells Pluripotent cells have the capacity to dif-
ferentiate into three germ layers: endoderm, ectoderm
and mesoderm. In turn, these multipotent cells can give
rise to terminally differentiated cell types. Ectoderm
gives rise to neuroectoderm and NPCs, which can finally
be differentiated into neuronal or glial cells (i.e. astro-
cytes and oligodendrocytes). During neurodevelopment
strict temporal and spatial expression of patterning fac-
tors determine cell fate. The most pivotal transcription
factors are SMAD transcription factors, which play a
fundamental role in transforming growth factor β
(TGFβ) and bone morphogenic protein (BMP) signaling
[54]. In these pathways two different classes of receptor-
regulated SMAD transcription factors, SMAD1/5/8 and
SMAD2/3, are responsible for the respective signaling
pathway. Inhibition of both classes of SMAD transcrip-
tion factors is in turn a defining part of neuralation as
their inhibition leads to the formation of the neural tube
[55]. During indirect neuronal differentiation, antagoniz-
ing TGFβ and BMP receptors causes dual SMAD
inhibition, and has been shown effective in iPSC differ-
entiation to neural cells [55], yielding over 80% of PAX6
positive neural progenitor cells (NPCs). Currently, NPC
yields have been improved by the use of more stable,
specific, and efficient small molecules [56]. NPCs in turn
can be differentiated to a mixed population of neuronal
cells. Specific morphogens can be applied directing a
specific cell fate. Sonic hedgehog induces a ventral fate
such as GABAergic and motor neurons or sonic hedge-
hog in combination with retinoic acid induces midbrain
dopaminergic neurons [55, 57–59].
To overcome laborious methods and impure yields,
direct conversion of iPSCs to neurons was developed
[60, 61] (Fig. 3). Viral overexpression of Ngn2 yielded a
pure population of excitatory glutamatergic neurons
within 2 weeks, called iN cells [62]. Besides the quick
and efficient aspects of directed differentiation, it also al-
lows for a pure single cell type culture. This can be an
advantage in order to study cell type-specific pheno-
types, which can be diluted out in mixed neuronal cul-
tures, and therefore not detected. In the scope of AD
research, this enables the definition of pathogenic contri-
butions of distinct cell types.
Astrocytes Until recently, astrocyte differentiation pro-
tocols were laborious and inefficient [63, 64]. By apply-
ing astrocyte-specific morphogens to NPCs, such as
fibroblast growth factor 2, Heregulin-1β, insulin-like
growth factor 1 and Activin A, functional astrocytes can
now be derived within 30 days from the NPC stage [65].
Alternatively, astrocytes can be differentiated from glial
progenitor cells (GPCs). GPCs are generated similar to
NPCs, however, platelet-derived growth factor was
added during progenitor development. Addition of N2,
B27, serum and Leukemia inhibitory factor to the GPCs
Fig. 4 Different approaches of creating human AD cell models. The classical patient-specific approach starts with somatic cells from sAD or fAD
patients and healthy control subjects. After reprogramming and differentiation cultures of patient-derived cells are compared to HCS-derived
cells. In the monogenic / isogenic approach somatic cells are taken from either fAD patients or healthy controls. Using gene-editing technologies
the fAD mutation is corrected or a fAD mutation is introduced into HCS cells. Alternatively, a sAD risk gene can be introduced or modified in HCS
cells, such as APOE. After differentiation of into the desired cell type, these modified cells are compered to their isogenic controls, reducing
interpatient variation
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resulted in formation of astrocytes after a total culture
time of 6 to 8 weeks [66]. Similar to induced neurons, it
is also possible to directly convert fibroblasts to astro-
cytes by the forced overexpression of NFIA, NFIB and
SOX9, yielding functional astrocytes in 2 weeks [67].
However, this was only shown for murine fibroblasts.
Human fibroblasts could be directly converted to
astrocyte-like precursors by applying a chemical cocktail
(histone deacetylase inhibitor valproic acid, the GSK3β
inhibitor CHIR99021, the TGFβ inhibitor 616,452, the
lysine specific histone demethylase LSD1 inhibitor tra-
nylcypromine, the cyclic AMP inducer forskolin, and a
histone methylation inhibitor DZNep). Astrocyte-like
precursors had to be further differentiated into astro-
cytes but the efficiency was rather low with 15% GFAP
positive and 40% S100β positive cells [68].
Simplified protocols repurposed commercial primary
astrocyte maintenance medium for astrocyte induction
when applied to NPCs [69]. Both types of methods
yielded functionally active astrocytes, which were able to
take up glutamate and showed an immune response to
several stimuli [65, 66, 69], including Aβ peptides, mak-
ing these cells especially suitable to elucidate pathome-
chanisms in AD. This was evident by the switch from
supportive glycolytic astrocytes, to oxidative, reactive as-
trocytes in cells expressing a PS1 fAD mutation [70], as
well as a lack of neuronal support shown in sAD iPSC-
astrocyte models [71, 72]. This supports the general un-
derstanding that astrocytes in AD lose their homeostatic
support function and gain a toxic effect, thereby actively
contribute to neuronal dysfunction in AD.
Microglia The development of microglia does not have
an ectodermal origin, in fact, this cell type is derived
from mesodermal hematopoietic stem cells, specifically
yolk sack-derived c-Myb-independent primitive macro-
phages [73]. It was not until recently that feasible micro-
glia differentiation protocols were developed (see [74]
for a complete overview). In short, recent studies pushed
the development of erythromyeloid progenitors (EMPs),
which are then directed to myelopoiesis by application
of morphogens such as interleukin 3, and macrophage
colony stimulating factor (M-CSF), additional factors are
optional [75, 76], with one study using an initial selec-
tion step [77]. Further, maturation and microglial enrich-
ment requires supplementation with CSFR1 ligand
interleukin 34 instead of M-CSF [78]. IPSC-microglia
were able to phagocytose fibrilar Aβ [75], express AD
relevant genes such as APOE and TREM2 [75, 78], and
were reactive in co-culture with neurons expressing fAD
mutations [79]. Furthermore, these genes were upregu-
lated when microglia were treated with fibrilar Aβ [75].
In addition, studies focusing on other neurodegenerative
disorders have found specific phagocytosis deficits in
iPSC-microglia, a mechanism also known to be affected
in AD [80] indicating that iPSC-derived microglia could
be an appropriate cell model to study AD pathogenesis.
3-dimensional models Neural cells are routinely differ-
entiated in a conventional two-dimensional (2D) culture
setting. However, differentiating iPSCs in 3D cultures
has been shown to increase cellular maturation, evident
by elevated expression of synaptic marker synaptotagmin
and neural cell adhesion molecule 1 in NPC-derived
neurons [81]. It should be noted that these NPCs,
named ReN cells, did not originate from iPSCs. ReN
cells are immortalized human neural progenitor cells,
originally derived from the ventral mesencephalon re-
gion of the human fetal brain, which have the ability to
differentiate into neurons and glial cells. 3D cultures can
be established through culturing cells in scaffolds, such
as Matrigel or synthetic hydrogels, or scaffold-free by
self-organizing or transcription factor patterned orga-
noids [3, 60, 82–84]. Using single type cell cultures [60],
the effect of 3D culture conditions can be easily analysed
for a certain cell type while the microenvironment, espe-
cially in hydrogel-based 3D cultures, is controllable.
However, single cells do not recapitulate the complexity
of neurons interacting with each other and with glial
cells. On the other hand, the microenvironment and ac-
cess to nutrients in self-organizing organoids cannot be
controlled well, in addition to lack of cytoarchitectural
structures. Patterned 3D corticospheres allow for the de-
velopment of structured cortical lamination comprising
of both superficial and deep cortical layer neurons, in-
cluding non-reactive astrocytes [84]. Allowing the
spheres to grow in suspension rather than on semi-solid
Matrigel or hydrogel enables the access of transcription
factors and thus closer control of the cell microenviron-
ment. However, to achieve matured 3D organoids the
center will be deprived of nutrients and oxygen, creating
a necrotic core, which may confound meaningful results
[3]. To overcome this, vasculature will need to be inte-
grated into the organoids, which has been tried, but is
still in a preliminary stage when using iPSCs (see [85]
for more comprehensive review). While all 3D model
systems have their advantages and disadvantages, evi-
dently, these models showed valuable improvements to
understanding AD pathology as mentioned below.
Even though iPSC-derived neural cells can mimic AD
pathomechanisms to a certain extent in 2D cultures, the
presence of robust Aβ plaque and neurofibrillary tangle
pathology is overtly absent [81]. By using 3D cultures,
Aβ peptides are trapped in the matrix and not removed
during medium changes and can therefore form aggre-
gates in the 3D environment. Evidently, fAD models
showed increase Aβ aggregations in hydrogel-based
neuro-organoids [3] and single cell models [81]. Another
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major finding was that Matrigel-based 3D cell cultures
expressed 4RTau isoforms, which were not detected in
2D cultures [81] at the same time point. In long-term
cultures (~ 6 months) of dopaminergic neurons, 4RTau
expression was observed also in 2D [86]. In addition to
Aβ and Tau pathology, other AD-related pathways such
as P21-activated kinase (PAK) were also found to be dys-
regulated in fAD cells in 3D but not in 2D [60]. PAK sig-
nalling is sensitive to mechanotransduction, which may
explain why this pathway is affected by fAD mutations
in 3D cultures, but is due to its absence not affected in
2D cultures. When exposed to Aβ aggregates a signifi-
cant PAK-mediated response was observed, which was
absent in 2D cultures [60]. Using 3D iPSC-neuronal
models could allow for the study of AD relevant patho-
mechanisms in a setting that more closely reflects the in
vivo context.
AD pathophysiology in iPSC-derived cells
Aβ and tau pathology A prominent pathological feature
of AD, the increased production of Aβ42, Aβ40 and in-
creased Aβ42/40 ratio, was replicated in iPSC-derived
mixed neuronal cultures generated from fAD fibroblasts
[63, 87–89] and also in fAD NPCs [90]. However, Aβ
pathology was shown to be cell type specific, as fAD and
sAD fibroblasts did not secrete increased levels of Aβ40
[89]. Not only neurons but also fAD astrocytes were
shown to secrete increased levels of Aβ42 and displayed
reduced capacity to take up Aβ42 [70, 91], evidently
showing that astrocytes are not mere bystanders in AD
pathology. Besides aberrant Aβ metabolism, AD is also
defined by the presence of hyperphosphorylated Tau ag-
gregates. As described above, iPSC-derived neurons are
known to be resemble immature neurons and do not ex-
press 4RTau in the timeframe of in vitro neuronal differ-
entiation [92]. 4RTau isoforms are more prone to
aggregate due to the additional microtubule-binding do-
main. When iPSC-neurons were cultured for an ex-
tended period of time, up to 356 days in vitro, a shift
from solely 3RTau expression to co-expression with
4RTau was observed [93].
Even in the absence of 4RTau expression, iPSC-
neurons from both fAD and sAD patients showed an in-
crease in phosphorylated tau (pTau) [89, 94]. In fAD
neurons carrying an APP duplication (APPdp), major
Tau kinase GSK-3β showed increased activity which
was rescued by β-secretase inhibition [89]. In addition,
extracellular application of Aβ to HCS-derived iPSC-
neurons induced Tau phosphorylation without affecting
total Tau protein levels [95].
Even though most hallmarks were prominent in mixed
neuronal cells derived from fAD patients, sAD patient-
derived neuronal cells did not show a robust Aβ42/40 ra-
tio or pTau increase [63, 89, 96, 97]. An explanation for
these irregular observations in sAD neurons is the ex-
tensive variation of genetic background as described
above. In addition, the heterogeneity of these cultures
could mask distinct pathomechanisms in specific cell
types. Using pure cultures of distinct neuronal subtypes
could indicate which cell type contributes to specific dis-
ease mechanisms in sAD [89, 98].
APP cleavage Elevated Aβ production in neuronal cells
is caused by aberrant APP processing. In iPSC-neurons
the APPV717F mutation caused increased generation of
Aβ and sAPPβ [87], induced by mislocalization and en-
richment of APP in early endosomes. As BACE-1 shows
highest activity in early endosomes, the accumulation of
APP in its close proximity enables BACE-1 to readily
cleave an abundance of APP. Enlarged endosomes have
been observed in APPdp neurons but not in fAD neurons
carrying the PSEN1ΔE9 mutation [89, 99]. Nonetheless,
in the absence of enlarged or increased numbers of
endosomes, a decrease in APP endo- and transcytosis
was found [100]. In addition, elevated levels of Rab11
were observed - a molecule playing a prominent role in
receptor recycling and transport. Endocytosis of low-
density lipoprotein (LDL) was also shown to be defect-
ive, with the decrease of LRP1 surface expression sug-
gested as causative mechanism. These endocytosis deficits
were rescued with β-secretase inhibition and were not
dependent on the specific fAD mutation (e.g. APP or pre-
senilin 1 (PS1)) [100]. Consistently, sAD neuronal models
also displayed deficits in endocytosis, for example by de-
crease of the endocytosis-mediating protein clathrin [97].
The presence of endosome pathology independent of AD
type or presence of APP or PS1 mutations, indicate that
endocytosis and vesicle recycling may be a fundamental
factor in AD pathogenesis.
APOE As the presence of the APOE4 allele is the major
genetic risk factor in sAD, this field of research has re-
cently refocussed on neural models expressing different
APOE variants, using either isogenic or patient derived
cells distinguished based on APOE status [71, 72, 101].
ApoE is mainly expressed by astrocytes in the brain, and
only expressed by neurons under stress conditions or
trauma [102]. Patient-derived iPSC-astrocyte models car-
rying homozygous APOE3 or APOE4 secreted ApoE
with a different lipidation status, apoE4 lipoprotein par-
ticles were less lipidated compared to ApoE3 particles
[72]. Furthermore, isogenic homozygous APOE4 astro-
cytes both produced and secreted less ApoE than
APOE3/3 cells [71]. Gene regulation in APOE4/4 astro-
cytes was different compared to APOE3/3 astrocytes,
with genes associated with lipid metabolism being prom-
inently affected. Additionally, APOE4/4 astrocytes were
less efficient in clearing Aβ42 which was shown to be a
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lysosome dependent effect [71]. APOE4/4 astrocytes had
a decreased ability to support neuronal and synaptic
homeostasis, as neurons in co-culture expressed de-
creased amounts of neuronal and synaptic markers, in
addition to decreased survival rates shown for isogenic
[71], and patient-derived iPSC-astrocytes [72].
Neurons carrying the APOE4/4 allele showed in-
creased Aβ40, Aβ42 and sAPPβ secretion as well as ele-
vated Tau phosphorylation [71, 101]. Interestingly,
inhibition of Aβ production did not decrease pTau in
these cells. In a mixed neuronal culture expressing
ApoE4, especially GABAergic neurons showed promin-
ent degeneration due to increased apoptosis [101]. De-
fective GABAergic neurons have previously been
described in (pre-clinical) AD, and non-demented sub-
jects carrying APOE4, which can cause network hyperex-
citability [103]. During differentiation, APOE4/4 cells
take on a neuronal fate earlier than APOE3/3 cells and
lose their ability to proliferate [71]. Subsequently,
APOE4 neurons showed an increase in synaptic density
and neurotransmitter release, eventhough synaptic
genes were downregulated, indicating the presence of
an overcompensatory mechanism. These structural al-
terations could lead to network hyperexcitability, a
known phenomenon in AD described above. Corre-
sponding to endosomal pathology found in sAD and
fAD neurons described earlier, APOE4/4 neurons also
displayed an increased number of early endosomes. Gen-
etic correction of APOE4/4 to APOE3/3 decreased these
phenotypes [71, 101]. The APOE4/4 effects were also
ameliorated by small molecule structure corrector
PH002, which changes the conformation of ApoE4,
resembling the conformation of ApoE3, as physio-
logical Aβ40/Aβ42 ratio was restored and pTau levels
were decreased [101]. In addition, neuronal cells from
a patient lacking the APOE gene (APOE −/−), showed
a phenotype similar to APOE3/3 neurons, indicating
that ApoE4 could have a gain of toxic function.
Next to astrocytes, microglia are the second major
contributor of ApoE, especially plaque-associated
ApoE, in the AD brain [104]. IPSC-microglia carrying
the APOE4/4 genotype showed a positive regulation
of immune system-related genes, whereas genes
involved in cell movement and development were
downregulated [71]. These cells had shorter and fewer
processes compared to APOE3/3 microglia and
showed slower phagocytosis of Aβ42. However, when
seeded in neuronal organoids, APOE4/4 microglia dis-
play longer processes. Microglia with shorter pro-
cesses have been described to be more efficient in Aβ
uptake in the brain, indicating APOE4/4 microglia in
the 3D environment have a reduced ability to sense
Aβ42, which resulted in an increase in extracellular
Aβ levels in the neuro-organoid.
Synaptic pathology Aβ has been described to interfere
with synaptic processes and mediate synaptic degener-
ation and toxicity (reviewed in [105]). Neuronal and
astrocytic iPSC-derived cells are electrophysiologically
functional evident by spontaneous and evoked activity
[89, 95, 106]. In addition, pre- and post-synaptic markers
have been detected within close proximity, indicating
the presence of functional synapses. Hence, iPSC-
derived models enable the study of synaptic function
and dysfunction. Synaptotoxic processes previously
established in other AD models have likewise been ob-
served in iPSC-derived neurons. Application of Aβ to
healthy iPSC-neurons reduced the number of synaptic
recycling pool (RP) vesicles but did not affect synaptic
vesicle release or the abundance of pre-synaptic puncta
[95]. The RP vesicle deficit was caused by a defective
synaptic vesicle reuptake mechanism, whereas the exo-
cytosis kinetics were unchanged (e.g. no change in syn-
aptic vesicle release). Both, exogenous Aβ application
and endogenous Aβ in fAD neurons failed to show pre-
synaptic mechanistical effects [89, 95]. However, in the
post-synapse deficits were detected in the form of re-
duced post-synaptic puncta, and reduced AMPA
receptor-mediated mEPSCs, indicating that Aβ had a
pronounced post-synaptic effect in iPSC neurons [95].
Interestingly, pre- and postsynaptic protein levels were
also unaffected in cultures of sAD patient-derived gluta-
matergic neurons in which Aβ and pTau levels were not
dysregulated [98]. This could imply that either Aβ and/
or pTau pathology is needed for a synaptotoxic pheno-
type, or the mere presence of one neuronal cell type
(glutametergic neurons) cannot recapitulate the intricacy
of a complex in vivo synaptic system.
Endoplasmic reticulum and mitochondrial stress
Mitochondrial metabolism, ER homeostasis and lysosomal
clearance are essential to maintain neuronal and glial
functions. In AD, however, these pivotal organelles have
been implicated in contributing to neuronal degeneration.
Early pathological events include the accumulation of mis-
folded protein in the ER, triggering a stress mechanism
called the unfolded protein response (UPR) [107]. Un-
folded protein can be sequestered and cleared by autoph-
agy, which appears to be dysfunctional in AD. The UPR
was upregulated in fAD and sAD iPSC-neurons [63], as
well as in healthy iPSC-neurons after application of Aβ,
where ER stress proteins LC3-II, BiP and CHOP were in-
creased [95]. The aberrant accumulation of these proteins
recapitulated the aforementioned deficits in autophagy.
Accordingly, autophagy markers LC3-II and p62 levels
where increased in fAD fibroblasts and neurons [108,
109]. In addition, decreased acidification of lysosomes,
and increased levels of early endosomes/lysosomes were
detected, indicating that the autophagic degradation phase
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was obstructed and lysosomal functioning was compro-
mised [109]. Further, presenilin-deficient iPSC-neurons
showed altered lysosomal function, reduced autophagy
and decreased levels of cytosolic and nuclear calcium
[108]. Dysfunctional calcium homeostasis was also ob-
served in iPSC-astrocytes derived from a patient with the
PSEN1ΔE9 mutation, contributing to loss of homeostatic
neuronal support by astrocytes [70].
Oxidative stress, caused by increased mitochondrial
ROS production, is a central process in normal aging.
However, aberrant ROS production is observed in AD
brains and has been linked to disease progression. Alter-
ations in mitochondrial membrane composition, struc-
ture and subcellular localization of mitochondria were
reported in AD [110]. Accordingly, increased ROS levels
were observed in iPSC-derived neurons and astrocytes
from fAD and sAD patients [63, 98]. Interestingly, pro-
tein levels of mitochondrial oxidative phosphorylation
chain complexes were upregulated in sAD neurons in
the absence of alterations in Aβ or pTau, indicating that
mitochondrial dysfunction may be an early event up-
stream of Aβ or Tau pathology [98].
Conclusions
Stem cell-based disease models have the potential to in-
duce a paradigm shift in biomedical research. Although
several concerns still limit the value and validity of iPSC-
based studies, most of these limitations can be overcome
by following some general guidelines. Studies on iPSC-
based modeling of AD are often not reproducible or show
opposite results. Better standardization of differentiation
protocols – currently most labs use their own protocols,
better characterization of the obtained cell cultures and
use of more defined media and coatings will reduce the
variability among labs and increase reproducibility. As de-
scribed above, another concern, which is related to poor
reproducibility, is the heterogeneity among different indi-
viduals and the heterogenous nature of sAD. To overcome
this limitation, higher donor numbers, patients as well as
controls, will be necessary. Alternatively, isogenic cells
should be used instead of AD patient-derived cells, wher-
ever possible. This further allows the analysis of specific
disease risk genes, such as APOE or TREM2. To increase
cellular maturity of iPSC-derived cells, which is lost dur-
ing reprogramming of adult somatic cells, 3D cell cultures
and organoid technologies represent a major step forward.
Taken together, iPSCs – either patient-derived or iso-
genic – constitute a breakthrough in modeling human
diseases. Although several hurdles still have to be over-
come, this technique allows understanding the earliest
events in AD and connecting them to their underlying
molecular mechanisms, providing the basis for identifi-
cation of disease pathomechanisms and new therapeutic
targets.
Abbreviations
2D: Two-dimensional; 3D: Three-dimensional; AD: Alzheimer’ s disease;
APOE: Apolipoprotein E; APP: Amyloid precursor protein; Aβ: Amyloid-β;
Cas: CRISPR-associated protein; CRISPR: Clustered regularly interspaced short
palindromic repeats; EMP: Erythromyeloid progenitors; fAD: Familial AD;
hFib: Human fibroblasts; HPC: Hematopoietic progenitor cell; IL: Interleukin;
iN cell: Induced neuronal cell; iPSC: Induced pluripotent stem cell;
NCAM1: Neural cell adhesion molecule 1; NPCs: Neural progenitor cells;
PAK: P21-activated kinaseren; PS1: Presenilin 1 protein; PSEN: Presenilin;
PSEN1: Presenilin 1 gene; p-Tau: Phosphorylated tau; RanBP17: RAN binding
protein 17; sAD: Sporadic AD
Acknowledgements
We thank Stephanie Davaz, Debora Wanner, Julian Birnbaum for fluorescence
images and Manuel Gersbacher for creating the APP processing figure.
Authors’ contributions
CT drafted the manuscript, SDL and CT wrote it. Both authors read and
approved the final version.
Funding
CT and SDL was supported by a grant from the Neuroscience Center Zurich,
University of Zurich, Switzerland and from the Betty and David Koetser
Foundation for Brain Research, Zurich, Switzerland.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Received: 20 March 2019 Accepted: 25 June 2019
References
1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global
prevalence of dementia: a systematic review and metaanalysis. Alzheimer's
Dementia. 2013;9(1):63–75 e2.
2. Gammon K. Neurodegenerative disease: brain windfall. Nature. 2014;
515(7526):299–300.
3. Raja WK, Mungenast AE, Lin YT, Ko T, Abdurrob F, Seo J, et al. Self-
organizing 3D human neural tissue derived from induced pluripotent stem
cells recapitulate Alzheimer's disease phenotypes. PLoS One. 2016;11(9):
e0161969.
4. Mansour AA, Goncalves JT, Bloyd CW, Li H, Fernandes S, Quang D, et al. An
in vivo model of functional and vascularized human brain organoids. Nat
Biotechnol. 2018;36(5):432–41.
5. Rajendran L, Annaert W. Membrane trafficking pathways in Alzheimer's
disease. Traffic (Copenhagen, Denmark). 2012;13(6):759–70.
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress
and problems on the road to therapeutics. Science. 2002;297:353–6.
7. Konietzko U. Gains and losses on the road to understanding Alzheimer's
disease. Swiss Med Wkly. 2015;145:w14233.
8. Chasseigneaux S, Allinquant B. Functions of Aβ, sAPPα and sAPPβ :
similarities and differences. J Neurochem. 2012;120(Suppl. 1):99–108.
9. Tackenberg C, Nitsch RM. The secreted APP ectodomain sAPPα, but not
sAPPβ, protects neurons against Aβ oligomer-induced dendritic spine loss
and increased tau phosphorylation. Molecular Brain. 2019;12(1):29.
10. Siegel G, Gerber H, Koch P, Bruestle O, Fraering PC, Rajendran L. The
Alzheimer's disease gamma-secretase generates higher 42:40 ratios for beta-
amyloid than for p3 peptides. Cell Rep. 2017;19(10):1967–76.
11. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's
disease. Nat Rev Neurosci. 2007;8(7):499–509.
12. Bakota L, Brandt R. Tau biology and tau-directed therapies for Alzheimer's
disease. Drugs. 2016;76(3):301–13.
Leeuw and Tackenberg Translational Neurodegeneration            (2019) 8:21 Page 10 of 13
13. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to
beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A. 2002;99:
6364–9.
14. Tackenberg C. Human tau-dependent toxicity in APP transgenic cultures
depends on calcium influx through N-methyl-D-aspartate receptors. Matters.
2016. https://doi.org/10.19185/matters.201602000028.
15. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid
beta-protein dimers isolated from Alzheimer cortex directly induce tau
hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A.
2011;108:5819–24.
16. Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, et al. Tau
reduction prevents Abeta-induced defects in axonal transport. Science.
2010;330(6001):198.
17. Tcw J, Goate AM. Genetics of beta-Amyloid Precursor Protein in Alzheimer's
Disease. Cold Spring Harbor perspectives in medicine. 2017;7(6). https://doi.
org/10.1101/cshperspect.a004457.
18. Selkoe DJ. Alzheimer's disease. Cold Spring Harbor perspectives in biology.
2011;9(2):600–14.
19. Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, et al.
Early-onset autosomal dominant Alzheimer disease: prevalence, genetic
heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65:664–70.
20. F C. Nongenetic Risk Factors for Alzheimer’s Disease. In: D G, E S, editors.
Neurodegenerative Diseases. London: Springer; 2014.
21. Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harbor
perspectives in medicine. 2012;2(10). https://doi.org/10.1101/cshperspect.
a006296.
22. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport
protein. Annu Rev Genomics Hum Genet. 2000;1:507–37.
23. Michaelson DM. APOE epsilon4: the most prevalent yet understudied risk
factor for Alzheimer's disease. Alzheimer's Dementia. 2014;10(6):861–8.
24. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, et
al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's
disease to form novel monofibrils. Isoform apoE4 associates more efficiently
than apoE3. J Clin Invest. 1994;94(2):860–9.
25. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al.
Human apoE isoforms differentially regulate brain amyloid-beta peptide
clearance. Sci. Transl. Med. 2011;3(89):89ra57.
26. Kim J, Yoon H, Basak J, Kim J. Apolipoprotein E in synaptic plasticity and
Alzheimer's disease: potential cellular and molecular mechanisms. Mol Cells.
2014;37(11):767–76.
27. Robinson M, Lee BY, Hane FT. Recent Progress in Alzheimer's disease
research, part 2: genetics and epidemiology. J Alzheimers Dis. 2017;57(2):
317–30.
28. Karch CM, Cruchaga C, Goate AM. Alzheimer's disease genetics: from the
bench to the clinic. Neuron. 2014;83(1):11–26.
29. Galatro TF, Holtman IR, Lerario AM, Vainchtein ID, Brouwer N, Sola PR, et al.
Transcriptomic analysis of purified human cortical microglia reveals age-
associated changes. Nat Neurosci. 2017;20(8):1162–71.
30. Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JCM, Sajti E, et al.
An environment-dependent transcriptional network specifies human
microglia identity. Science. 2017;356(6344). https://doi.org/10.1126/science.
aal3222.
31. Oberheim NA, Takano T, Han X, He W, Lin JH, Wang F, et al. Uniquely
hominid features of adult human astrocytes. J Neurosci. 2009;29(10):
3276–87.
32. Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, et al.
Purification and characterization of progenitor and mature human
astrocytes reveals transcriptional and functional differences with mouse.
Neuron. 2016;89(1):37–53.
33. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse
embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:
663–76.
34. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al.
Induction of pluripotent stem cells from adult human fibroblasts by defined
factors. Cell. 2007;131:861–72.
35. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A
more efficient method to generate integration-free human iPS cells. Nat
Methods. 2011;8:409–12.
36. Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia enhances
the generation of induced pluripotent stem cells. Cell Stem Cell. 2009;5(3):
237–41.
37. Bar-Nur O, Brumbaugh J, Verheul C, Apostolou E, Pruteanu-Malinici I, Walsh
RM, et al. Small molecules facilitate rapid and synchronous iPSC generation.
Nat Methods. 2014;11(11):1170–6.
38. Marson A, Foreman R, Chevalier B, Bilodeau S, Kahn M, Young RA, et al. Wnt
signaling promotes reprogramming of somatic cells to pluripotency. Cell
Stem Cell. 2008;3(2):132–5.
39. Mali P, Chou BK, Yen J, Ye Z, Zou J, Dowey S, et al. Butyrate greatly
enhances derivation of human induced pluripotent stem cells by
promoting epigenetic remodeling and the expression of pluripotency-
associated genes. Stem cells (Dayton, Ohio). 2010;28(4):713–20.
40. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, et al.
Induction of pluripotent stem cells from primary human fibroblasts with
only Oct4 and Sox2. Nat Biotechnol. 2008;26(11):1269–75.
41. Singh VK, Kalsan M, Kumar N, Saini A, Chandra R. Induced pluripotent stem
cells: applications in regenerative medicine, disease modeling, and drug
discovery. Front Cell Dev Biol. 2015;3:2.
42. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, et al. Human induced
pluripotent stem cells free of vector and transgene sequences. Science.
2009;324(5928):797–801.
43. Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of
transgene-free human pluripotent stem cells using a vector based on
Sendai virus, an RNA virus that does not integrate into the host genome.
Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2009;85(8):348–62.
44. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient
reprogramming to pluripotency and directed differentiation of human cells
with synthetic modified mRNA. Cell Stem Cell. 2010;7(5):618–30.
45. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hamalainen R, et
al. piggyBac transposition reprograms fibroblasts to induced pluripotent
stem cells. Nature. 2009;458(7239):766–70.
46. Studer L, Vera E, Cornacchia D. Programming and reprogramming cellular
age in the era of induced pluripotency. Cell Stem Cell. 2015;16(6):591–600.
47. Miller JD, Ganat YM, Kishinevsky S, Bowman RL, Liu B, Tu EY, et al. Human
iPSC-based modeling of late-onset disease via progerin-induced aging. Cell
Stem Cell. 2013;13(6):691–705.
48. Buchwalter A, Hetzer MW. Nucleolar expansion and elevated protein
translation in premature aging. Nat Commun. 2017;8(1):328.
49. Mertens J, Paquola AC, Ku M, Hatch E, Bohnke L, Ladjevardi S, et al. Directly
reprogrammed human neurons retain aging-associated transcriptomic
signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell.
2015;17(6):705–18.
50. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M.
Direct conversion of fibroblasts to functional neurons by defined factors.
Nature. 2010;463(7284):1035–41.
51. Victor MB, Richner M, Hermanstyne TO, Ransdell JL, Sobieski C, Deng PY, et
al. Generation of human striatal neurons by microRNA-dependent direct
conversion of fibroblasts. Neuron. 2014;84(2):311–23.
52. Richner M, Victor MB, Liu Y, Abernathy D, Yoo AS. MicroRNA-based
conversion of human fibroblasts into striatal medium spiny neurons. Nat
Protoc. 2015;10(10):1543–55.
53. Victor MB, Richner M, Olsen HE, Lee SW, Monteys AM, Ma C, et al. Striatal
neurons directly converted from Huntington's disease patient fibroblasts
recapitulate age-associated disease phenotypes. Nat Neurosci. 2018;21(3):
341–52.
54. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev.
2005;19(23):2783–810.
55. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer
L. Highly efficient neural conversion of human ES and iPS cells by dual
inhibition of SMAD signaling. Nat Biotechnol. 2009;27(3):275–80.
56. Pauly MG, Krajka V, Stengel F, Seibler P, Klein C, Capetian P. Adherent vs.
Free-Floating Neural Induction by Dual SMAD Inhibition for Neurosphere
Cultures Derived from Human Induced Pluripotent Stem Cells. Front Cell
Dev Biol. 2018;6:3. https://doi.org/10.3389/fcell.2018.00003.
57. Nadadhur AG, Emperador Melero J, Meijer M, Schut D, Jacobs G, Li KW, et
al. Multi-level characterization of balanced inhibitory-excitatory cortical
neuron network derived from human pluripotent stem cells. PLoS One.
2017;12(6):e0178533.
58. Cooper O, Hargus G, Deleidi M, Blak A, Osborn T, Marlow E, et al.
Differentiation of human ES and Parkinson's disease iPS cells into ventral
midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a
and specific regionalization by retinoic acid. Mol Cell Neurosci. 2010;45(3):
258–66.
Leeuw and Tackenberg Translational Neurodegeneration            (2019) 8:21 Page 11 of 13
59. Sances S, Bruijn LI, Chandran S, Eggan K, Ho R, Klim JR, et al. Modeling ALS
with motor neurons derived from human induced pluripotent stem cells.
Nat Neurosci. 2016;19(4):542–53.
60. Zhang D, Pekkanen-Mattila M, Shahsavani M, Falk A, Teixeira AI, Herland A. A 3D
Alzheimer's disease culture model and the induction of P21-activated kinase
mediated sensing in iPSC derived neurons. Biomaterials. 2014;35(5):1420–8.
61. Sagal J, Zhan X, Xu J, Tilghman J, Karuppagounder SS, Chen L, et al.
Proneural transcription factor Atoh1 drives highly efficient differentiation of
human pluripotent stem cells into dopaminergic neurons. Stem Cells Transl
Med. 2014;3(8):888–98.
62. Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, et al. Rapid single-
step induction of functional neurons from human pluripotent stem cells.
Neuron. 2013;78:785–98.
63. Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, et al. Modeling
Alzheimer's disease with iPSCs reveals stress phenotypes associated with
intracellular Aβ and differential drug responsiveness. Cell Stem Cell. 2013;12:
487–96.
64. Krencik R, Zhang SC. Directed differentiation of functional astroglial
subtypes from human pluripotent stem cells. Nat Protoc. 2011;6(11):1710–7.
65. Lundin A, Delsing L, Clausen M, Ricchiuto P, Sanchez J, Sabirsh A, et al.
Human iPS-derived Astroglia from a stable neural precursor state show
improved functionality compared with conventional astrocytic models.
Stem Cell Reports. 2018;10(3):1030–45.
66. Santos R, Vadodaria KC, Jaeger BN, Mei A, Lefcochilos-Fogelquist S, Mendes
APD, et al. Differentiation of inflammation-responsive astrocytes from glial
progenitors generated from human induced pluripotent stem cells. Stem
Cell Reports. 2017;8(6):1757–69.
67. Caiazzo M, Giannelli S, Valente P, Lignani G, Carissimo A, Sessa A, et al.
Direct conversion of fibroblasts into functional astrocytes by defined
transcription factors. Stem Cell Reports. 2015;4(1):25–36.
68. Tian E, Sun G, Sun G, Chao J, Ye P, Warden C, et al. Small-molecule-based
lineage reprogramming creates functional astrocytes. Cell Rep. 2016;16(3):
781–92.
69. Tcw J, Wang M, Pimenova AA, Bowles KR, Hartley BJ, Lacin E, et al. An
efficient platform for astrocyte differentiation from human induced
pluripotent stem cells. Stem Cell Reports. 2017;9(2):600–14.
70. Oksanen M, Petersen AJ, Naumenko N, Puttonen K, Lehtonen S, Gubert
Olive M, et al. PSEN1 mutant iPSC-derived model reveals severe astrocyte
pathology in Alzheimer's disease. Stem Cell Reports. 2017;9(6):1885–97.
71. Lin YT, Seo J, Gao F, Feldman HM, Wen HL, Penney J, et al. APOE4 Causes
Widespread Molecular and Cellular Alterations Associated with Alzheimer's
Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron. 2018;
98(6):1141–54 e7.
72. Zhao J, Davis MD, Atagi Y, Shinohara M, Graff-Radford NR, Younkin SG, et al.
APOE epsilon4/epsilon4 diminishes neurotrophic function of human iPSC-
derived astrocytes. Hum Mol Genet. 2017;26(14):2690–700.
73. Nayak D, Roth TL, McGavern DB. Microglia development and function. Annu
Rev Immunol. 2014;32:367–402.
74. Haenseler W, Rajendran L. Concise Review: Modeling Neurodegenerative
Diseases with Human Pluripotent Stem Cell-Derived Microglia. Stem cells
(Dayton, Ohio). 2019;37(6):724–30.
75. Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, et
al. iPSC-derived human microglia-like cells to study neurological diseases.
Neuron. 2017;94(2):278–93 e9.
76. McQuade A, Coburn M, Tu CH, Hasselmann J, Davtyan H, Blurton-Jones M.
Development and validation of a simplified method to generate human
microglia from pluripotent stem cells. Mol Neurodegener. 2018;13(1):67.
77. Douvaras P, Sun B, Wang M, Kruglikov I, Lallos G, Zimmer M, et al. Directed
differentiation of human pluripotent stem cells to microglia. Stem Cell
Reports. 2017;8(6):1516–24.
78. Haenseler W, Sansom SN, Buchrieser J, Newey SE, Moore CS, Nicholls FJ, et
al. A highly efficient human pluripotent stem cell microglia model displays
a neuronal-co-culture-specific expression profile and inflammatory response.
Stem Cell Reports. 2017;8(6):1727–42.
79. Park J, Wetzel I, Marriott I, Dreau D, D'Avanzo C, Kim DY, et al. A 3D human
triculture system modeling neurodegeneration and neuroinflammation in
Alzheimer's disease. Nat Neurosci. 2018;21(7):941–51.
80. Garcia-Reitboeck P, Phillips A, Piers TM, Villegas-Llerena C, Butler M, Mallach
A, et al. Human induced pluripotent stem cell-derived microglia-like cells
harboring TREM2 missense mutations show specific deficits in phagocytosis.
Cell Rep. 2018;24(9):2300–11.
81. Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D'Avanzo C, et al. A three-
dimensional human neural cell culture model of Alzheimer's disease.
Nature. 2014;515(7526):274–8.
82. Papadimitriou C, Celikkaya H, Cosacak MI, Mashkaryan V, Bray L, Bhattarai P,
et al. 3D culture method for Alzheimer's disease modeling reveals
Interleukin-4 rescues Abeta42-induced loss of human neural stem cell
plasticity. Dev Cell. 2018;46(1):85–101 e8.
83. Mahoney MJ, Anseth KS. Three-dimensional growth and function of neural
tissue in degradable polyethylene glycol hydrogels. Biomaterials. 2006;
27(10):2265–74.
84. Pasca AM, Sloan SA, Clarke LE, Tian Y, Makinson CD, Huber N, et al.
Functional cortical neurons and astrocytes from human pluripotent stem
cells in 3D culture. Nat Methods. 2015;12(7):671–8.
85. Lee CT, Bendriem RM, Wu WW, Shen RF. 3D brain organoids derived
from pluripotent stem cells: promising experimental models for brain
development and neurodegenerative disorders. J Biomed Sci. 2017;
24(1):59.
86. Beevers JE, Lai MC, Collins E, Booth HDE, Zambon F, Parkkinen L, et al. MAPT
genetic variation and neuronal maturity Alter isoform expression affecting
axonal transport in iPSC-derived dopamine neurons. Stem Cell Reports.
2017;9(2):587–99.
87. Muratore CR, Rice HC, Srikanth P, Callahan DG, Shin T, Benjamin LN, et al.
The familial Alzheimer's disease APPV717I mutation alters APP processing
and tau expression in iPSC-derived neurons. Hum Mol Genet. 2014;23(13):
3523–36.
88. Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, et al. Modeling
familial Alzheimer's disease with induced pluripotent stem cells. Hum Mol
Genet. 2011;20(23):4530–9.
89. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, et al. Probing
sporadic and familial Alzheimer's disease using induced pluripotent stem
cells. Nature. 2012;482:216–20.
90. Sproul AA, Jacob S, Pre D, Kim SH, Nestor MW, Navarro-Sobrino M, et
al. Characterization and molecular profiling of PSEN1 familial
Alzheimer's disease iPSC-derived neural progenitors. PLoS One. 2014;
9(1):e84547.
91. Liao MC, Muratore CR, Gierahn TM, Sullivan SE, Srikanth P, De Jager PL, et al.
Single-cell detection of secreted Abeta and sAPPalpha from human IPSC-
derived neurons and astrocytes. J Neurosci. 2016;36(5):1730–46.
92. Sato C, Barthelemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-
Balsarotti J, et al. Tau kinetics in neurons and the human central nervous
system. Neuron. 2018;97(6):1284–98 e7.
93. Sposito T, Preza E, Mahoney CJ, Seto-Salvia N, Ryan NS, Morris HR, et al.
Developmental regulation of tau splicing is disrupted in stem cell-derived
neurons from frontotemporal dementia patients with the 10 + 16 splice-site
mutation in MAPT. Hum Mol Genet. 2015;24(18):5260–9.
94. Yang J, Zhao H, Ma Y, Shi G, Song J, Tang Y, et al. Early pathogenic event of
Alzheimer's disease documented in iPSCs from patients with PSEN1
mutations. Oncotarget. 2017;8(5):7900–13.
95. Nieweg K, Andreyeva A, van Stegen B, Tanriover G, Gottmann K. Alzheimer's
disease-related amyloid-beta induces synaptotoxicity in human iPS cell-
derived neurons. Cell Death Dis. 2015;6:e1709.
96. Ochalek A, Mihalik B, Avci HX, Chandrasekaran A, Teglasi A, Bock I, et al.
Neurons derived from sporadic Alzheimer's disease iPSCs reveal elevated
TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation.
Alzheimers Res Ther. 2017;9(1):90.
97. Lee HK, Velazquez Sanchez C, Chen M, Morin PJ, Wells JM, Hanlon EB, et al.
Three dimensional human neuro-spheroid model of Alzheimer's disease
based on differentiated induced pluripotent stem cells. PLoS One. 2016;
11(9):e0163072.
98. Birnbaum JH, Wanner D, Gietl AF, Saake A, Hock C, Nitsch RM, et al.
Oxidative stress and altered mitochondrial protein expression in the
absence of amyloid-beta and tau pathology in iPSC-derived neurons from
sporadic Alzheimer’s disease patients. Stem Cell Res. 2018;27:121–30.
99. Woodruff G, Young JE, Martinez FJ, Buen F, Gore A, Kinaga J, et al. The
Presenilin-1 ΔE9 mutation results in reduced γ-secretase activity, but not
Total loss of PS1 function, in isogenic human stem cells. Cell Rep. 2013;5:
974–85.
100. Woodruff G, Reyna SM, Dunlap M, Van Der Kant R, Callender JA, Young JE,
et al. Defective transcytosis of APP and lipoproteins in human iPSC-derived
neurons with familial Alzheimer's disease mutations. Cell Rep. 2016;17(3):
759–73.
Leeuw and Tackenberg Translational Neurodegeneration            (2019) 8:21 Page 12 of 13
101. Wang C, Najm R, Xu Q, Jeong DE, Walker D, Balestra ME, et al. Gain of toxic
apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by
a small-molecule structure corrector. Nat Med. 2018;24(5):647–57.
102. Mahley RW, Huang Y. Apolipoprotein e sets the stage: response to injury
triggers neuropathology. Neuron. 2012;76(5):871–85.
103. Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease.
Arch Neurol. 2009;66(4):435–40.
104. Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, et
al. Loss of TREM2 function increases amyloid seeding but reduces plaque-
associated ApoE. Nat Neurosci. 2019;22(2):191–204.
105. Tackenberg C, Ghori A, Brandt R. Thin, Stubby or Mushroom: Spine
Pathology in Alzheimer's. In: Lahiri DK, editor. Advances in Alzheimer's
Research. 2. Sharjah: Bentham Science Publishers; 2014. p. 375–94.
106. Iovino M, Agathou S, Gonzalez-Rueda A, Del Castillo Velasco-Herrera M,
Borroni B, Alberici A, et al. Early maturation and distinct tau pathology in
induced pluripotent stem cell-derived neurons from patients with MAPT
mutations. Brain. 2015;138(Pt 11):3345–59.
107. Hoozemans JJ, van Haastert ES, Nijholt DA, Rozemuller AJ, Eikelenboom P,
Scheper W. The unfolded protein response is activated in pretangle
neurons in Alzheimer's disease hippocampus. Am J Pathol. 2009;174(4):
1241–51.
108. Reddy K, Cusack CL, Nnah IC, Khayati K, Saqcena C, Huynh TB, et al.
Dysregulation of nutrient sensing and CLEARance in Presenilin deficiency.
Cell Rep. 2016;14(9):2166–79.
109. Martin-Maestro P, Gargini R, A Sproul, A, Garcia E, Anton LC, Noggle S, et al.
Mitophagy Failure in Fibroblasts and iPSC-Derived Neurons of Alzheimer's
Disease-Associated Presenilin 1 Mutation. Front Mol Neurosci. 2017;10:291.
110. DuBoff B, Feany M, Gotz J. Why size matters - balancing mitochondrial
dynamics in Alzheimer's disease. Trends Neurosci. 2013;36(6):325–35.
Leeuw and Tackenberg Translational Neurodegeneration            (2019) 8:21 Page 13 of 13
